Cellectis S.A. (NASDAQ:CLLS) Short Interest Down 6.5% in November

Cellectis S.A. (NASDAQ:CLLS) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 131,400 shares, a drop of 6.5% from the November 15th total of 140,500 shares. Based on an average trading volume of 56,100 shares, the days-to-cover ratio is currently 2.3 days.

Cellectis Trading Down 1.7 %

Shares of CLLS traded down $0.03 during mid-day trading on Monday, reaching $1.73. The stock had a trading volume of 55,402 shares, compared to its average volume of 51,203. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The firm has a market cap of $96.16 million, a price-to-earnings ratio of -1.33 and a beta of 3.09. The business’s fifty day moving average is $1.92 and its 200 day moving average is $2.09. Cellectis has a 52-week low of $1.70 and a 52-week high of $3.77.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The business had revenue of $18.05 million during the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same quarter in the prior year, the company posted ($0.31) earnings per share. On average, sell-side analysts predict that Cellectis will post -0.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CLLS has been the topic of a number of research reports. Barclays cut their price objective on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. StockNews.com assumed coverage on Cellectis in a research report on Sunday. They set a “sell” rating on the stock.

Hedge Funds Weigh In On Cellectis

Several large investors have recently made changes to their positions in the stock. First Affirmative Financial Network purchased a new position in shares of Cellectis during the third quarter worth $45,000. Long Focus Capital Management LLC grew its position in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after acquiring an additional 130,000 shares in the last quarter. XTX Topco Ltd purchased a new stake in Cellectis during the second quarter worth about $29,000. Finally, Principal Financial Group Inc. lifted its position in shares of Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after purchasing an additional 12,467 shares in the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.